MORE►
Panna Sharma
[Image: Black_Kira/istockphoto]
Lantern Pharma Preps 2026 Trial for Rare Pediatric Brain Cancer After FDA Guidance
by Quincy Preston | Oct 14, 2025
The North Texas biotech, which uses AI to accelerate cancer drug development, received FDA feedback to advance a new clinical study targeting a rare childhood brain tumor.
by Glenn Hunter |
Sep 24, 2025
At Dallas’ iC3 Summit, leaders from Texas and across the U.S. pointed to AI, new state initiatives like Proposition 14, and potential federal reforms as keys to speeding innovation and keeping America competitive in life sciences.
MORE►
Dallas Biotech Launches Open-Access AI Tool Targeting One of Brain Drug Discovery’s Toughest Hurdles
by Quincy Preston |
Aug 20, 2025
With just 2% to 6% of small-molecule drugs able to cross the blood-brain barrier, researchers and drugmakers face steep odds. Lantern Pharma’s tool, the company’s CEO says, could be “a paradigm shift” in developing treatments for conditions ranging from brain cancers to Parkinson’s disease.
MORE►
by Glenn Hunter |
Apr 30, 2025
Dallas Innovates, in partnership with the Dallas Regional Chamber, once again is recognizing the most innovative leaders in AI in Dallas-Fort Worth. From visionaries and mavericks to transformers and academics, AI 75's class of 2025 are the AI pacesetters you need to know now.
MORE►
Lantern Pharma Subsidiary Starlight Therapeutics Names New Chief Medical Officer to Oversee Clinical Trials
by Lance Murray | Jan 19, 2024
Marc Chamberlain, M.D., has been appointed as the Chief Medical Officer at Starlight Therapeutics.
Starlight Therapeutics is a Dallas-based Lantern Pharma subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options.
In his role as CMO, Chamberlain will oversee the company’s upcoming clinical trials focused on several serious and complex brain-related conditions: glioblastoma and other high-grade gliomas (aggressive types of brain tumor), brain metastases in adults (secondary brain tumors originating from cancer elsewhere in the body), and two types of pediatric brain tumors — atypical teratoid rhabdoid tumors (ATRT) and diffuse intrinsic pontine glioma (DIPG)....
MORE►
by Lance Murray |
May 2, 2023
The "blood-brain barrier" acts like a highly selective firewall, preventing an estimated 98% of drugs from entering the brain—making it a major hurdle in the development of brain and central nervous system drugs. Lantern Pharma has recently developed what it calls "highly accurate AI algorithms" to predict the ability of a drug or compound to pass through the barrier.
MORE►
by Lance Murray |
Mar 2, 2023
Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members....
MORE►
by Quincy Preston |
Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
MORE►
Panna Sharma [Image: DI composite, Photos courtesy of Lantern]
Lantern Pharma Teams Up with National Cancer Institute to Predict Drug Effectiveness on Tumors
by Lance Murray | Oct 7, 2019
This alum of Dallas startup accelerator Health Wildcatters is working with the National Cancer Institute's Developmental Therapeutics Branch on precision research and treatments.
MORE►
![Erica Kosemund, Chief Brand Officer, Choctaw Nation of Oklahoma; Gillian Breidenbach, Chief Partnership Officer, North Texas FWC Organizing Committee; Chief Gary Batton, Chief of Choctaw Nation of Oklahoma; Monica Paul, Executive Director of Dallas Sports Commission and President of North Texas FWC Organizing Committee; John Hobbs, Senior Executive Officer of Communications, Choctaw Nation of Oklahoma; and Heidi Grant, Senior Executive Officer of Commerce Administration, Choctaw Nation of Oklahoma, celebrate Choctaw Casinos & Resorts becoming an Official Dallas World Cup 2026 Host City Supporter. [Photo: North Texas FWC Organizing Committee/Choctaw Casinos & Resorts]](https://s24806.pcdn.co/wp-content/uploads/2025/12/FIFA-Choctaw-dec-2025.jpg)
